PACE 212\* RCVD AT 81302004 9:06:08 AM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-111 \* DNIS:8729307 \* CSID: \* DURATION (mm-ss)-10-102 O-103 - 10-103 O-103 - 10-103 O-103 O-103

## RECEIVED CENTRAL FAX CENTER

AUG 1 3 2004



Serial No.: 09/936,377 Docket No.: BM45379

## In the Claims:

Claims 1-24 (Cancelled)

- 25. (Previously Presented): An isolated polypeptide comprising a member selected from the group consisting of
  - (a) the amino acid sequence SEQ ID NO:2; and
  - (b) an immunogenic fragment of at least 15 contiguous amino acids of SEQ ID NO:2; wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.
- 26. (Cancelled)
- 27. (Previously Presented): The isolated polypeptide of claim 25, wherein the polypeptide is according to (a).
- 28. (Cancelled)
- 29. (Previously Presented): The isolated polypeptide of claim 25, wherein the polypeptide is according to (b).
- 30. (Cancelled)
- 31. (Previously Presented): The isolated polypeptide of claim 25, wherein the immunogenic fragment of (b) comprises at least 20 contiguous amino acids of SEQ ID NO:2, wherein the immunogenic fragment, when administered to a subject in a suitable composition which can include an adjuvant, or a suitable carrier coupled to the polypeptide, induces an antibody or T-cell mediated immune response that recognizes the polypeptide SEQ ID NO:2.